Guslandi Mario, Giollo Patrizia, Testoni Pier Alberto
Gastroenterology Unit, S. Raffaele University Hosptial, Milan, Italy.
Eur J Gastroenterol Hepatol. 2003 Jun;15(6):697-8. doi: 10.1097/00042737-200306000-00017.
Probiotics can be useful in the treatment of inflammatory bowel disease. In a previous report, the non-pathogenic yeast Saccharomyces boulardii was found to be beneficial in the maintenance treatment of Crohn's disease. The aim of this study was to assess the efficacy of S. boulardii in ulcerative colitis patients.
A group of 25 patients with a mild to moderate clinical flare-up of ulcerative colitis received additional treatment with S. boulardii 250 mg three times a day for 4 weeks during maintenance treatment with mesalazine. These patients were unsuitable for steroid therapy. Before and after treatment, Rachmilewitz's clinical activity index was calculated. The probiotic treatment was considered a therapeutic success only when the final score was lower than 6.
Of the 24 patients who completed the study, 17 attained clinical remission; this was confirmed endoscopically.
Our preliminary results suggest that S. boulardii can be effective in the treatment of ulcerative colitis. Controlled studies with this probiotic agent are warranted.
益生菌可用于治疗炎症性肠病。在之前的一份报告中，发现非致病性酵母布拉氏酵母菌对克罗恩病的维持治疗有益。本研究的目的是评估布拉氏酵母菌对溃疡性结肠炎患者的疗效。
一组25例轻至中度溃疡性结肠炎临床发作的患者，在接受美沙拉嗪维持治疗期间，额外接受布拉氏酵母菌治疗，每天3次，每次250毫克，持续4周。这些患者不适合使用类固醇疗法。治疗前后计算拉赫米列维茨临床活动指数。仅当最终评分低于6分时，益生菌治疗才被视为治疗成功。
在完成研究的24例患者中，17例实现了临床缓解；内镜检查证实了这一点。
我们的初步结果表明，布拉氏酵母菌可有效治疗溃疡性结肠炎。有必要对这种益生菌制剂进行对照研究。
